An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).

Rita TrozziSandra TuyaertsDaniela AnnibaliAlejandro Herreros PomaresLotte BoogPeter Van DamKarin LeunenChristophe DerooseHans TrumFrédéric Amant

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)

Fulvestrant may control tumor growth in recurrent/metastatic estrogen receptor-positive low-grade gynecological malignancies of specific histology. Further studies are needed to confirm these results.

Keyphrases

estrogen receptor
low grade
phase ii study
high grade
squamous cell carcinoma
small cell lung cancer
open label
locally advanced
metastatic breast cancer
radiation therapy
case control
placebo controlled